Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse

NCT00112554 is registered in ClinicalTrials.gov with Vion Pharmaceuticals as lead sponsor.

NCT NCT00112554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00112554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse
Lead sponsor
Vion Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2005
Completion date
March 31, 2008
Enrollment
420 (estimated)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia